Document is current
Any future updates will be listed below
-
Authors
Oh, Jeeyoung
Sekijima, Yoshiki
Mochizuki, Hideki
Joon Kim, Byoung
Min, Ju-Hong
Katsuno, Masahisa
Yin Tan, Cheng
Lee, Yi-Chung
Misumi, Yohei
Zhao, Weizhi
Chan-Daniels, Amy
Chao, Chi-Chao
-
Funding
Funding for this research was provided by:
Alnylam Pharmaceuticals
- License Information
-
More Information
Article History
Received: 5 December 2025
Accepted: 3 February 2026
First Online: 4 March 2026
Declarations
:
: Dr. Oh reports nothing to disclose. Dr. Sekijima has received speaker honoraria and research grants from Alnylam Pharmaceuticals and Pfizer, institutional grants from Alnylam Pharmaceuticals and Pfizer, and royalties from Pfizer. Dr. Mochizuki reports nothing to disclose. Dr. Kim reports nothing to disclose. Dr. Min reports nothing to disclose. Dr. Katsuno reports nothing to disclose. Dr. Tan reports nothing to disclose. Dr. Lee reports nothing to disclose. Dr. Misumi declares a research grant from Alnylam Pharmaceuticals. Dr. Zhao and Dr. Chan-Daniels are employees of Alnylam Pharmaceuticals, Inc. and report ownership of equity in Alnylam Pharmaceuticals, Inc. Dr. Chao reports nothing to disclose.
: The study protocol and amendments were approved by relevant Institutional Review Boards or Independent Ethics Committees. This information is detailed in the supplementary material, Table . Written informed consent was obtained from each participant. The study was conducted in accordance with all applicable regulatory requirements, the current guidelines of Good Clinical Practice, and principles originating from the Declaration of Helsinki.
